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EXPERT SURVEY FOR INCREMENTAL COST-EFFECTIVENESS RATIO 
(ICER) THRESHOLD RANGE IN KOREA: DISCRETE CHOICE 
EXPERIMENTS
Lee J, Ko S
Pﬁzer Korea, Seoul, South Korea
OBJECTIVES: This study was performed to elicit ICER threshold range in Korea and 
to investigate the magnitude of relative inﬂuence of main attributes to reimbursement 
decision. METHODS: This study was based on experts survey using discrete choice 
experiments (DCE). DCE is stated preference method, in which respondents are 
requested to express preferences for sets of hypothetical choice alternatives constructed 
according to experimental design principles. Total 39 respondents (22 from the gov-
ernment or academia and 17 from industry) were responded to this survey among 95 
selected experts who were working in pharmacoeconomics ﬁeld. We identiﬁed 6 
attributes (disease severity, availability of alternative therapy, burden of disease, ICER, 
uncertainty of cost-effectiveness ratio and budget impact) which are considered as 
main decision factors for reimbursement decision. Literatures related to reimburse-
ment decision in Australia, UK, Canada and Korea were comprehensively investigated 
to elicit these attributes. 18 choice sets having two alternatives were selected using 
fractional factorial design (FFD). Each coefﬁcient of 6 attributes and probabilities of 
a recommendation response by ICER range were estimated. RESULTS: Total 1346 
observations were analyzed using probit model. 4 attributes (severity, burden, alterna-
tive, ICER) signiﬁcantly inﬂuenced on respondents’ choice on reimbursement decision 
(p  0.001). If the disease is severe and rare, the probability of recommending the 
alternative as cost-effective is higher. The lower ICER, the higher the probability of 
choosing the alternatives. ICER range threshold from survey results is 70,000,000 
KRW approximately. If industry group were excluded in the analysis, the ﬁgure 
reduced to 40,000,000 KRW. CONCLUSIONS: This study showed that severity, 
burden, alternative, ICER is important factor for reimbursement decision in Korea as 
well expected. The ICER threshold estimated from this study between the estimators 
from previous studies. The study design and/or respondent characteristics could affect 
these ﬁgures.
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IMPACT OF MISSING DATA ON POTENTIAL CONFOUNDERS IN 
PERINATAL PHARMACOEPIDEMIOLOGIC STUDIES USING 
ADMINISTRATIVE DATABASES
Bérard A, Nakhai-Pour HR, Kulaga S
University of Montreal, Montreal, QC, Canada
OBJECTIVES: Administrative databases are increasingly being used in perinatal phar-
macoepidemiology. Although such studies have increased statistical power, they are 
prone to biases due to lack of information on potential confounders. Hence, the 
objective was to quantify the degree of bias introduced by the lack of data on smoking 
status and maternal pre-pregnancy weight in the association between gestational 
exposure to antidepressants and the risk of low birth weight (LBW) infants. 
METHODS: The Quebec Pregnancy Registry was used to sample a cohort of women 
who had delivered a liveborn singleton, and answered a self-administered question-
naire on lifestyles during pregnancy and family history. The association between 
antidepressant use during pregnancy and the risk of LBW was calculated unadjusting 
for smoking status and maternal pre-pregnancy weight using the Registry data. The 
association was further estimated adjusting for smoking and maternal pre-pregnancy 
weight using the questionnaire data. Percent bias in the Registry estimate was calcu-
lated using Schneeweiss’ method. RESULTS: Overall, the unadjusted estimate (Regis-
try data) for the association between antidepressant use during pregnancy and the risk 
of LBW was 1.16 (p  .05). Adjusting for smoking status resulted in an estimate of 
0.99 (p  0.05), and for maternal pre-pregnancy weight, 1.19 (p  0.05). The percent 
bias introduced by the non-adjustment for smoking and maternal pre-pregnancy 
weight using only the Registry data was 13%, and did not change the direction of the 
effect. CONCLUSIONS: Although data on potential confounders are often missing in 
perinatal pharmacoepidemiologic studies using administrative databases, the bias that 
results for the non-adjustment does not necessarily invalidate ﬁndings.
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HOW TO GAIN HIGH DATA QUALITY IN A NON-INTERVENTIONAL 
TRIAL TAKING THE LIVE-COM STUDY AS EXAMPLE
Schön H1, Theobald K2, Schädlich PK3
1CSG mbH, Berlin, Germany, 2Sanoﬁ-Aventis Germany, Frankfurt, Germany, 3IGES Institut 
GmbH, Berlin, Germany
OBJECTIVES: The increasing scientiﬁcness and complexity of non-interventional 
studies is facing new operational and quality management aspects to gain high level 
quality data and results. Therefore it is crucial to implement quality measurements as 
part of the overall study design. METHODS: A non-interventional, comparative 
multicenter, representative cross sectional cost evaluation study was conducted (LIVE-
COM1). The study retrospectively documented and compared diabetes-speciﬁc 
resource utilisation and patient-reported outcomes (PRO) associated with insulin 
administration in patients with type-2 diabetes mellitus over six months. The study 
was performed in accordance with the recommendations to improve quality and 
transparency of non-interventional studies of the German Association of Research-
Based Pharmaceutical Companies and according to Good Epidemiological Practice. A 
detailed study plan, containing scientiﬁc objectives and statistical methods was devel-
oped before start of study and approved by the responsible Ethic Committee. In 
addition a feasibility assessment of the case record forms and PRO-instruments was 
performed in advance. A total of 4000 randomly selected primary care units were 
invited to participate in LIVE-COM. Throughout the study a close telephone monitor-
ing with the sites was implemented, also to ensure the collection of the PRO data from 
the patient. A detailed in-house review of the case record forms, double data entry, 
query resolutions and source data veriﬁcation at 10% of the sites was implemented. 
RESULTS: In total 1731 patients with signed informed consent were included in the 
study at 138 study centres in Germany. Overall only 1.3% of the documented patient 
data showed missing values and the validity of the data was high. Only in rare cases 
imputation algorithms were applied or data were excluded from analyses. CONCLU-
SION: The implementation of data quality management procedures and close contact 
with the study sites can deliver high quality data comparable to clinical studies. 1Long 
Acting Insulin Glargine Versus Insulin Detemir Cost Evaluation Comparison.
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THE MONDRIAAN PROJECT: THE DUTCH HEALTH CARE LANDSCAPE 
AS A POPULATION LABORATORY
Klungel OH1, Rietveld MC2, de Groot MC3, Stolk RP4, Postma MJ5, Leufkens HG1,  
Egberts TC3, Hövels AM6, van de Langerijt L7, Hoes AW3, Grobbee DE3
1Utrecht University, Utrecht, The Netherlands, 2University Medical Center Utrecht, Utrecht,, 
The Netherlands, 3University Medical Center Utrecht, Utrecht, The Netherlands, 4University 
Medical Center Groningen, Groningen, The Netherlands, 5University of Groningen, 
Groningen, The Netherlands, 6GlaxoSmithKline The Netherlands, Zeist, The Netherlands, 
7Sanoﬁ-aventis The Netherlands B.V, Gouda, The Netherlands
OBJECTIVES: To optimize routine health care databases in The Netherlands for 
pharmaco-epidemiologic and economic research in order to improve the beneﬁt-risk 
assessment and the assessment of the value of medicines in daily practice. The gap 
between pre-clinical pharmaceutical research and clinical and outcomes research 
hampers optimal beneﬁt-risk assessment and monitoring of new and existing medi-
cines as well as determining their value in daily practice. Although many excellent 
health care databases are available in The Netherlands for pharmaco-epidemiologic 
and –economic research, in isolation these data remain scattered, rather inaccessible 
and cover relatively inadequate population sample sizes and/or are rather limited in 
detail of the registered information. METHODS: In the ﬁrst phase we have linked 
pharmacy records from the National Foundation of Pharmaceutical Statistics (N  
12,000,000) on a patient base to several routine health care databases such as the 
Almere Health Care database (N  160,000), the Utrecht Health Project (N  20,000), 
and the AGIS claims database (N  1,000,000). To ensure protection of patient 
privacy, pseudonimisation and linkage was performed through a trusted third party 
(TTP). A data catalogue has been developed to allow simple queries over the integrated 
databases which will help in the design of pharmacoepidemiologic studies (incl. sample 
size calculations, assessment of completeness of data). In the second phase, we will 
include several other health care and research databases in The Netherlands (Lifelines, 
Interaction database (IADB), and the Northern GP registration). RESULTS: The pro-
posed research program will deliver a strong, large-scale, high-quality, internationally 
competitive data platform for innovative pharmaceutical research and provide the 
tools to improve beneﬁt-risk assessment of medicines.
CONCEPTUAL PAPERS & RESEARCH ON METHODS – Modeling Methods
PMC32
MULTI AGENT SIMULATION TECHNIQUES FOR DYNAMIC 
SIMULATION OF SOCIAL INTERACTION AND SPREAD OF DISEASES 
WITH DIFFERENT SEROTYPES
Endel G1, Schiller - Frühwirth I1, Popper N2, Miksch F2, Zauner G2, Breitenecker F3
1Hauptverband der Österreichischen Sozialversicherungsträger, Vienna, Vienna, Austria, 
2DWH—Simulation Services, Vienna, Vienna, Austria, 3Vienna University of Technology, 
Vienna, Vienna, Austria
OBJECTIVES: For modeling vaccination strategies and spreading of infectious dis-
eases by airborne infection or contact transmission detailed individual based simula-
tion is needed. A new technique modeling heterogeneous populations with age speciﬁc 
behavior and population dynamics during simulation is presented. METHODS: A 
multi agent based model is implemented. Requirements: Simulate long periods for long 
term effects; consider changing population structure; implement a social model to 
simulate individual contacts; and simulate various pathogens to differentiate between 
vaccine-covered and non-covered serotypesThe model consists of three parts. Popula-
tion part. Individual attributes for agents: Age, Gender, Infection State, Pregnancy 
(women only) and a unique ID-Number, Age Class and Infection Protocol are stored. 
Aging, Death and Birth of Agents is implemented. Parameters can be identiﬁed with 
real population data of Austria provided by “Statistik Austria”. Social part. Epidemics 
can be spread only through direct contact between two agents. Contacts can happen 
at home, at work, and randomly. Additional rules (f.e. age distribution of people in 
contact depending on the age of the persons) are deﬁned. Epidemics part. The proce-
dure of the epidemics part is depicting the contact based infections, carrying time and 
end of illness, including, time and age speciﬁc carrying time of special bacterial strains. 
Extra features for simulation of two or more pathogens in parallel are developed. 
RESULTS: The concept has been validated using detailed data for serious pneumococ-
cal indicated diseases for Austria. Stability analysis and dependency on starting param-
eters was examined. Results show stable realistic behavior for single serotype and 
competing serotypes. CONCLUSIONS: Using this dynamic modeling concept simula-
tion of non linear effects like herd immunity and serotype replacement is possible for 
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testing vaccination strategies. One of the main beneﬁts is that for parameterization 
and identiﬁcation no abstract values are used, so objectivity and traceability are 
assured.
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CRITICAL REVIEW OF ECONOMIC MODELS IN TYPE 2 DIABETES
Yi Y1, Bergman G2, Burslem K3, Philips Z4
1Mapi Values, Cheshire, UK, 2Mapi Values, Houten, The Netherlands, 3Boehringer Ingelheim 
Limited, Berkshire, UK, 4Mapi Values, Macclesﬁeld, UK
OBJECTIVES: To identify and critically appraise cost-effectiveness models developed 
to evaluate type 2 diabetes (T2D) treatments and to assess which types of treatment 
effects they capture. METHODS: A systematic search was performed in MEDLINE, 
EMBASE, Centre for Reviews and Dissemination databases at the University of York, 
and Health Economic Evaluation Database for the period to September 2008. The 
websites of Health Technology Assessment (HTA) bodies in different countries were 
also screened for relevant models. For each of the identiﬁed original models, details 
of the structure, data in- and outputs and consistency were extracted and critically 
appraised using published criteria. RESULTS: 78 articles and 41 HTAs reporting rel-
evant economic evaluations were identiﬁed. There were ten models with multiple 
publications, and a further ten models with one associated publication. The critical 
review demonstrated that most of the existing models had the same fundamental 
structure, used similar microsimulation techniques and were based on the same key 
data sources. However, the process for identiﬁcation of relevant data and their syn-
thesis, as well as the selection of outcomes was, at times, inconsistent and lacked 
transparency. The models differed according to which diabetes complications and 
treatment-related adverse events were captured. For example, just one model incor-
porated changes in patient weight, despite the fact that weight gain can be a side effect 
of some treatments, and weight loss a potential beneﬁt of others. CONCLUSIONS: 
Whilst many economic models exist in T2D, most share common features such as the 
model type. Identiﬁed shortcomings are lack of transparency in data identiﬁcation and 
evidence synthesis as well as the selection of the modelled outcomes. Future models 
should aim to include all relevant treatment outcomes, whether these relate to effects 
on underlying diabetes and its complications or to short- or long-term side effects of 
treatment.
PMC34
SEROTYPE-SPECIFIC TRANSMISSION DYNAMICS OF INVASIVE 
PNEUMOCOCCAL DISEASE AFTER VACCINATION WITH 7-VALENT 
PNEUMOCOCCAL CONJUGATE VACCINE
Snedecor SJ1, Botteman MF1, Strutton DR2
1Pharmerit North America LLC, Bethesda, MD, USA, 2Wyeth Research, Collegeville, PA, 
USA
OBJECTIVES: After the introduction of the 7-valent pneumococcal conjugate vaccine 
(Prevnar®) in the US, the incidence of invasive pneumococcal disease (IPD) caused by 
the 7 vaccine serotypes declined dramatically in vaccinated children as well as unvac-
cinated adults (via herd effect beneﬁt). In 2008, a transmission dynamic equation 
model was developed to capture direct and indirect vaccination effects. This model 
accurately predicted the total incidence of IPD (caused by all serotypes) after Prevnar® 
introduction. This original model was reﬁned in the present analysis to predict the 
dynamics of IPD caused by speciﬁc serotypes. METHODS: The model simulates the 
acquisition of asymptomatic carriage of pneumococci and the development of fatal 
and non-fatal IPD among vaccinated and unvaccinated individuals aged 2, 2–4, 5–17, 
18–49, 50–64, and  65 years old. Categories of pneumococcal serotypes include 
PCV7-type (4, 6B, 9V, 14, 18C, 19F, and 23F) and non-PCV7-type (all others). The 
model was calibrated by approximating serotype-speciﬁc US IPD surveillance data 
from the years 1998–2006. RESULTS: The previous model structure ﬁt the disease 
incidence caused by the PCV7 serotypes quite well, but was inadequate to predict 
increases in disease caused by the non-PCV7 serotypes due to serotype replacement. 
Additionally, the surveillance data showed limited increase in IPD caused by non-
PCV7 serotypes in the vaccinated 2-year-old group. A subsequent recalibration and 
reformulation resulted in a revised model able to replicate closely the observed IPD 
incidence stratiﬁed by pneumococcal serotypes. CONCLUSIONS: The revised model 
validates the accuracy of the original model to replicate the incidence of IPD caused 
by PCV7 serotypes and may be used to predict the future incidence of disease given 
the increases in IPD caused by non-PCV7 serotypes.
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SCHIZOPHRENIA MODELING: MARKOV MODEL WITH MONTE-CARLO 
MICROSIMULATION
Dragomir A1, Angers JF1, Tarride JE2, Rouleau G1, Drapeau P1, Perreault S1
1University of Montreal, Montréal, QC, Canada, 2McMaster University, Hamilton, ON, 
Canada
Pharmacological strategies for schizophrenia have received increasing attention due to 
the development of new and costly drug therapies. Evaluating their relative costs and 
beneﬁts in Canada requires modeling the natural course of schizophrenia. OBJEC-
TIVES: To develop a Markov model with 1st-order Monte-Carlo simulations to simu-
late the natural course of newly diagnosed schizophrenic patients. METHODS: Six 
discrete disease states deﬁned the Markov model: 1): ﬁrst episode—FE; 2) low depen-
dency state—LDS; 3) high dependency state—HDS; 4) Stable; 5) Well; and 6) Death. 
Patients’ movements between these disease states deﬁned 17 probability transitions 
to be estimated. The model was based on data from the Régie de l’assurance maladie 
du Québec and Med-Echo databases. All individuals aged 0–60 years with a newly 
diagnosis of schizophrenia between 1998 to 2006 were ﬁrst identiﬁed by ICD-9 codes. 
Using this data, 5 Cox proportional hazard models for competing risks were used to 
estimate the 17 probabilities of transition. Validation was conducted by comparing 
the model’s probability transitions’ predictions with the published literature. 
RESULTS: A total of 12,754 individuals were identiﬁed as newly diagnosed patients 
with schizophrenia. After the FE of schizophrenia, 69.8% of patients passed in LDS, 
11.2% in HDS, 1% in death state and 18% in Well state. The mean transition prob-
abilities after one year of follow-up were: FE to Well at 0.28 (oSD  0.10), FE to HDS 
at 0.11 (o0.05), FE to LDS at 0.60 (o0.08) and respectively FE to Death at 0.01 
(o0.01). The corresponding values were similar to those obtained from other published 
models. CONCLUSIONS: This model is the ﬁrst Canadian model incorporating 
transition probabilities adjusted for individual risk factors proﬁles using Canadian 
data. Future applications will include pricing and cost-effectiveness of new therapies 
for schizophrenia.
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CREATING NATIONAL WEIGHTS FOR PRIVATE INSURANCE 
DATABASE
Baser O1, Wang L2
1University of Michigan and STATinMED Research, Ann Arbor, MI, USA, 2STATinMED 
Research, Ann Arbor, MI, USA
OBJECTIVES: To create national weights to project a private database to the US 
insured population controlling not only for socio-demographic factors but also health 
status. METHODS: The Medicare Expenditure Survey was used as the basis of adjust-
ment methodology. First, we subset the data source to the study population, then used 
multivariate logistic regression to construct demographics and case-mix based weights 
that were applied to make the data similar to the national sample. Propensity Score 
Matching and Raking algorithm is combined to create the adjusted weights. The 
socioeconomic characteristics included in the model were the age of the head of the 
household, percentage of the patients who were female, race, geographic region and 
income level. We derived two variables to capture general health status of the member. 
First, Charlson Index scores were generated to capture the level and burden of comor-
bidity. Secondly, we created an indicator variable to represent patients with chronic 
conditions. This variable was derived by convening two physician panels to review all 
medical conditions reported by the survey sample. RESULTS: Private data were more 
likely to be male, white, older, and chronic (p  0.0000). Adjusted weight values for 
the Commercial group ranged from 13.47 to 26.39 with median 16.35. The projected 
US population by private database and MEPS data were similar in terms of socioeco-
nomic and clinical categories. As an outcomes measure, the predicted annual statin 
users from private data was 6,973,034. Statin users are predicted as 6,709,438 using 
MEPS data with MEPS weights. CONCLUSIONS: National projection of a private 
database requires adjustment from not only demographic factors but also case-mix 
differences related to health status. The created weights successfully balanced the 
population in terms of co-morbid conditions and chronic conditions as well as demo-
graphic factors.
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COMPARISON OF RISK ADJUSTMENT MODELS IN OUTCOMES 
RESEARCH
Baser O1, Gust C2, Dysinger A2, Yuce H3, Akin C1, Wang L2
1University of Michigan and STATinMED Research, Ann Arbor, MI, USA, 2STATinMED 
Research, Ann Arbor, MI, USA, 3STATinMED Research and The City University of New 
York, Brooklyn, NY, USA
OBJECTIVES: Matching and regression analysis are two approaches to estimate 
average treatment effect. Different matching techniques provide different results. 
Moreover, matching cannot control for unobserved bias. Using ProbChoice algorithm 
and Rosenbaum bounding approach, we aim to show how to choose strongly unmea-
sured variable must inﬂuence the selection process to undermine the implication of 
matching and regression analysis. METHODS: The Surveillance, Epidemiology, and 
End Results (SEER) Data is used for the analysis. For each patient, their hospital of 
care and associated hospital volume is computed. Patients in the high and low volume 
hospitals are matched in seven different ways in terms of demographic and clinical 
characteristics. Treatment costs are compared. The best technique is chosen by Prob-
Choice algorithm. Rosenbaum bonds estimated and Mantel and Haenszel test statistics 
is calculated to provide evidence on the degree to which any signiﬁcance results hinge 
on unconfoundedness assumption. RESULTS: A volume cohort was constructed con-
sisting of 19,375 female SEER-Medicare patients, aged 65, suffering an in situ and/or 
invasive breast cancer during 2003–2005 with surgical treatment performed at 567 
hospitals. Mahalobis matching is the one who created the best balanced comparable 
sets. After the matching, samples were similar in terms of race, comorbidity and 
adjuvant therapies. Under the assumption of no hidden bias, costs were lower of the 
high volume hospitals. (p  0.000). Results were insensitive to a bias that would double 
the odds of being treated high volume hospitals but sensitive to a bias that would 
triple the odds. CONCLUSIONS: There exist several matching techniques and the 
results depend the type of matching chosen. One needs to chose the technique best 
suitable for the data. Rosenbaum bonds provides evidence on sensitivity of the esti-
mated results with respect to unobservable factors that is not controlled by propensity 
score matching.
